Our Pipeline

PlatformTargetIndicationDISCOVERYPRE-CLINICALPHASE I/II
Boltbody ISAC HER2
  • HER2+ Breast Cancer
  • HER2 Low Breast Cancer
  • HER2+ Gastric Cancer
  • Other HER2+ Cancers

PHASE I/II

BDC-1001
Boltbody ISAC CEA
  • Non-Small Cell Lung Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Breast Cancer

PRE-CLINICAL

Boltbody ISAC PD-L1
  • Checkpoint Inhibitor Refractory Tumors

PRE-CLINICAL

Myeloid ModulatorTAM1
  • KRAS mutated cancer
  • TP53 mutated cancer

PRE-CLINICAL

BDC-1001

BDC-1001 is Boltbody ISAC that is  currently in clinical development for the treatment of patients with HER2-expressing solid tumors, including subsets with HER2-low tumors. We have designed BDC-1001 as an ISAC comprised of a HER2-targeting biosimilar trastuzumab conjugated to one of our proprietary TLR7/8 agonists to maximize the potential anti-tumor response.

BDC-1001 stimulates anti-tumor activity with a three-pronged approach: direct tumor cell killing by trastuzumab-mediated mechanisms, localized phagocytosis and elimination of HER2-expressing tumor cells by activated myeloid APCs, and durable immunity manifested by T cells reactive to tumor-associated antigens or neoantigens. These mechanisms are supported by our in vivo data demonstrating tumor elimination and immunological memory when treated with our BDC-1001 surrogates.